1-9 of 9
Jonathan Kell, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Clinical Benefit of Crenolanib, with or without Salvage Chemotherapy, in Multiply Relapsed, FLT3 Mutant AML Patients after Prior Treatment with Gilteritinib

Aaron D Goldberg, MDPhD, Mark B. Geyer, MD, Jonathan Kell, MD, Eros Di Bona, MD, Timothy S. Pardee, MDPhD, Rupali Bhave, MD, Michael R. Grunwald, MD, Giovanni Marconi, MD, Yijia Wang, MD MPH, Asif Pathan, PhD RPh, Boo Messahel, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 8–9.
https://doi.org/10.1182/blood-2020-139898
Published: 2020
Journal Articles

Routine Management, Healthcare Resource Use and Patient/Caregiver-Reported Outcomes of Patients with Transfusion-Dependent β-Thalassaemia in the United Kingdom: A Mixed Methods Observational Study

Farrukh Shah, MDMBBS,FRCPath, Paul Telfer, DM, FRCP, Mark Velangi, Shivan Pancham, Robert Wynn, Sally Pollard, Elizabeth Chalmers, Jonathan Kell, MD, Joe Hickey, PhD, Clark Paramore, MPH, Minesh Jobanputra, MD, Kate Ryan, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3550.
https://doi.org/10.1182/blood-2019-129930
Published: 2019
Journal Articles

Final Development of the First Generic Quality of Life and Symptoms Measure Specific for Hematological Malignancies: The HM-PRO

Pushpendra Goswami, PhD MSc, BPharm, Tatiana Ionova, DSc, Esther Natalie Oliva, PhD, Roger Else, Jonathan Kell, MD, Adele K. Fielding, MBBS,PhDFRCP,FRCPath, Daniel Jennings, Marina Karakantza, MD, Saad Al-Ismail, MD, Graham P. Collins, MA, MBBS, MRCP, FRCPath, DPhil, Stewart McConnell, Catherine Langton, Sam Salek, PhDRPh FFPM MCMS MRPSGB FESCP
Journal: Blood
Blood (2019) 134 (Supplement_1): 3484.
https://doi.org/10.1182/blood-2019-129030
Published: 2019
Journal Articles

Development of a Novel Patient-Reported Outcome Measure in Haematological Malignancy for Use in Routine Clinical Practice: Item Generation

Pushpendra Goswami, B.Pharmacy, MSc, Sam Salek, PhDRPh FFPM MCMS MRPSGB FESCP, Adele K. Fielding, MB BS, PhD FRCP, FRCPath, Jonathan Kell, MD, Saad Al-Ismail, MD, Esther Oliva, MD, Tatyana Ionova, PhD, Roger Else, Marina Karakantza, MD, Daniel Jennings, Anita Waldmann
Journal: Blood
Blood (2016) 128 (22): 5985.
https://doi.org/10.1182/blood.V128.22.5985.5985
Published: 2016
Journal Articles

Baseline Predictors of Mortality in Patients with Relapsed or Refractory Acute Myeloid Leukemia Treated with Vosaroxin Plus Cytarabine or Placebo Plus Cytarabine in the Phase 3 VALOR Study

Jeffrey E Lancet, MD, Farhad Ravandi, MD, Ellen K Ritchie, MD, Hamid Sayar, MD, Stephen A. Strickland, MD, Gary J Schiller, MD, Norbert Vey, MD, Harry P Erba, MD PhD, Arnaud Pigneux, Heinz-August Horst, MD PhD, Christian Recher, MD, Olatoyosi Odenike, MD, Angelo-Michele Carella, MD, Dominik Selleslag, MD, Jonathan Kell, MD, Utz Krug, MD, Leigh Page, Art DeVault, PhD, Shuling Hwang, MD, Adam R Craig, MD PhD, Robert K. Stuart, MD
Journal: Blood
Blood (2015) 126 (23): 2560.
https://doi.org/10.1182/blood.V126.23.2560.2560
Published: 2015
Journal Articles

A Randomised Comparison of Daunorubicin 90mg/m 2 Vs 60mg/m 2 in AML Induction: Results from the UK NCRI AML17 Trial in 1206 Patients

Alan K. Burnett, MD, Nigel Russell, Robert K. Hills, MA MSc DPhil, Jonathan Kell, MD MB, Jamie Cavenagh, Lars Kjeldsen, MD PhD, Mary Frances McMullin, MDFRCPath, FRCP, Paul Cahalin, Mike Dennis, Donald Milligan, MD, Richard E Clark, MBBS MD
Journal: Blood
Blood (2014) 124 (21): 7.
https://doi.org/10.1182/blood.V124.21.7.7
Published: 2014
Journal Articles

A Comparison of Single Dose Gemtuzumab Ozogamicin 3mg/m 2 and 6mg/m 2 Combined with Induction Chemotherapy in Younger Patients with AML: Data from the UK NCRI AML17 Trial

Alan K Burnett, MD, Nigel Russell, Robert K. Hills, MA MSc DPhil, Jamie Cavenagh, Jonathan Kell, MD MB, Gail Jones, Asim Khwaja, FRCPath, Mary Frances McMullin, MDFRCPath,FRCP, Mike Dennis, Donald Milligan, MD, Richard E Clark, MBBS MD
Journal: Blood
Blood (2014) 124 (21): 2308.
https://doi.org/10.1182/blood.V124.21.2308.2308
Published: 2014
Journal Articles

A Randomised Comparison of Clofarabine Versus Low Dose Ara-C As First Line Treatment for Older Patients with AML

Alan K Burnett, MD, ChB, FRCP, FRCPath, FMedSci, Nigel H. Russell, MD, Mary Frances McMullin, MD, Jonathan Kell, MD, MB, Sahra Ali, FRCPath, FRCP, BM, MRCP, MRCPath, Paul Moreton, Andrew H Wei, MBBS, PhD, Lars Kjeldsen, MD, PhD, Robert K. Hills, MA, MSc, DPhil
Journal: Blood
Blood (2012) 120 (21): 889.
https://doi.org/10.1182/blood.V120.21.889.889
Published: 2012
Journal Articles

A Comparison of Daunorubicin/Ara-C (DA) Versus Daunorubicin/Clofarabine (DClo) and Two Versus Three Courses of Total Treatment for Older Patients with AML and High Risk MDS: Results of the UK NCRI AML16 Trial

Alan K. Burnett, MD, Nigel H Russell, MD, Jonathan Kell, MD, MB, Lars Kjeldsen, MD, PhD, Donald Milligan, MD, FRCP, FRCPath, Paul Cahalin, Robert K. Hills, MA, MSc, DPhil
Journal: Blood
Blood (2012) 120 (21): 892.
https://doi.org/10.1182/blood.V120.21.892.892
Published: 2012